Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(T...(987 explains Dr. Lunsford. We also hav...),Health

Date:10/23/2007

987," explains Dr. Lunsford. "We also have used the Leksell Gamma Knife B, C and 4C units over the last 20 years. We now use the 4C unit and the Perfexion unit side by side in the same radiosurgical suite. We continue to use the original Leksell Gamma Knife U unit for radiobiological research." Since 1987, UPMC has performed almost 9,000 Leksell Gamma Knife surgeries and trained over 1,000 neurosurgeons, radiation oncologists, neuro-otologists and medical physicists in the appropriate usage of the Leksell Gamma Knife.

UPMC continues to use a full range of Elekta stereotactic systems including a new Elekta Synergy(R) S system for spinal radiosurgery that is going online next week. "Elekta has been a very collaborative partner," says Dr. Lunsford, "which is critical for the success of both academic institutions and companies like Elekta, because testing and product development occurs within these partnerships."

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state-of-the-art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) and Elekta Synergy(R) for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can b
'/>"/>

SOURCE Elekta, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference